Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.13
(
-0.52%
)
Bitcoin
73,941.37
(
0.00%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 59242

Monday, 02/18/2008 8:15:33 PM

Monday, February 18, 2008 8:15:33 PM

Post# of 257253
>Apropos generic Copaxone - The Indian company Natco has already launched the first generic Copaxone on May 07. As far as I know, they didn't challenge Teva's patents in court and sold their version only in India…<

We would know if they had challenged the US patent—they haven’t.

>I use past tense is because I no longer see the drug called Glatimer in their product list.<

Where’s our resident expert on Indian pharma? Please come forward!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today